Search results
Results from the WOW.Com Content Network
Dupixent is approved for inadequately controlled chronic rhinosinusitis (a long-standing inflammation of the sinuses) with nasal polyps, as an add-on maintenance treatment in adults and children aged 12 years and older.
The US Food and Drug Administration (FDA) has approved Dupixent (dupilumab) as an add-on maintenance treatment of adults with inadequately controlled chronic obstructive pulmonary disease (COPD) and an eosinophilic phenotype. Dupixent is the first biologic medicine approved in the US to treat these patients. Jean Wright, M.D.
Dupixent is the first biologic medication approved by the FDA for adults and children aged 6+ years with moderate to severe atopic dermatitis. It is taken subcutaneously (by injection) at 300 mg once every other week. What is a biologic drug?
Find answers to frequently asked questions about DUPIXENT® (dupilumab), a prescription medicine FDA-approved to treat six conditions. Including how to administer DUPIXENT®, common side effects, and results seen in DUPIXENT® clinical trials.
DUPIXENT® (dupilumab) is a dual inhibitor of IL-4 and IL-13 signaling and is approved for 6 indications. The mechanism of dupilumab action has not been definitively established. Serious adverse reactions may occur. Please see Important Safety Information and full Prescribing Information on website.
Dupilumab (Dupixent) is a biologic that is given by subcutaneous (under the skin) injection that may be used to treat the following inflammatory conditions:
Learn more about DUPIXENT® (dupilumab), the first and only FDA-approved biologic treatment for adults with inadequately controlled COPD (chronic obstructive pulmonary disease) and a high number of blood eosinophils.